- July 29, 2021
- Posted by: admin1
- Category: DPN Topics
Subject: Science and Technology
Context: Covishield, the made-in-India variant of Oxford-AstraZeneca’s AZD-1222 formulation, is the predominant vaccine being used in India’s mass immunisation programme against SARS-CoV-2, the Covid-19 virus.
- Interim results of VIN-WIN cohort study’), published in a special issue of the peer-reviewed Medical Journal Armed Forces India.
- The VIN-WIN study mentions results of other Covishield vaccine effectiveness studies as well
- This is the largest study from India evaluating Covid vaccine effectiveness so far
Study and findings
- Healthcare workers and frontline workers of the armed forces were among the first to get their jabs after India started vaccinating on January 16 this year.
- Till 30 May, 95.4% and 82.2% were partially and fully vaccinated (respectively),” says the study.
- The study used anonymised data from the existing Armed Forces Health Surveillance system which had been enhanced for monitoring Covid-19
- According to the study have showed a 93 per cent reduction in breakthrough infections after vaccination with Covishield.